S. 1041

119th Congress

Introduced

Affordable Prescriptions for Patients Act

Sponsored byRepublican:Sen. Cornyn, John [R-TX]TX· Introduced 13 mars 2025
Open on Congress.gov

3

Cosponsors

11

Actions

0

Amendments

1

Committees

—

Since introduced

Introduced
Committee
Passed Chamber
Passed Both
Enacted
Step 0 of 0
Latest action

Held at the desk.

21 juillet 2026·1 day ago

Summary

Introduced in Senate · Updated 24 juin 2025

Affordable Prescriptions for Patients Act

This bill limits in certain instances the number of patents that the manufacturer of a biologic drug can assert in a lawsuit against a company seeking to sell a biosimilar version of that drug. (A biologic drug is produced through natural processes or isolated from natural sources. A biosimilar version is substantially similar to the original biologic, which is the reference product, and is often marketed as a less expensive alternative.)

The bill's provisions apply to an existing framework that gives the biosimilar manufacturer an abbreviated path to Food and Drug Administration approval to sell the biosimilar. Specifically, if the biosimilar manufacturer completes certain actions under the framework, such as sharing certain information about its product with the reference product manufacturer, the bill limits the number of certain patents that the reference product manufacturer may assert in a lawsuit, such as patents that were filed more than four years after the reference product received market approval. The limit shall not apply to patents claiming certain methods for using the biologic drug.

The court in which the infringement lawsuit is filed may increase the limit if justice so requires or if there is good cause for the increase.

Timeline

11 actions

  1. Held at the desk.

    21 juillet 2026 · Floor

  2. Message on Senate action sent to the House.

    21 juillet 2026 · Floor

  3. Received in the House.

    21 juillet 2026 · Floor

  4. Passed Senate with amendments by Unanimous Consent.

    21 juillet 2026 · Floor

  5. Passed/agreed to in Senate: Passed Senate with amendments by Unanimous Consent.

    21 juillet 2026 · Floor

  6. Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.

    10 avril 2025 · Committee

  7. Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.

    10 avril 2025 · Committee

  8. Placed on Senate Legislative Calendar under General Orders. Calendar No. 44.

    10 avril 2025 · Calendars

  9. Placed on Senate Legislative Calendar under General Orders. Calendar No. 44.

    10 avril 2025 · Calendars

  10. Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.

    10 avril 2025 · Committee

  11. Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.

    10 avril 2025 · Committee

  12. Committee on the Judiciary. Ordered to be reported with amendments favorably.

    3 avril 2025 · Committee

  13. Committee on the Judiciary. Ordered to be reported with amendments favorably.

    3 avril 2025 · Committee

  14. Read twice and referred to the Committee on the Judiciary.

    13 mars 2025 · IntroReferral

  15. Read twice and referred to the Committee on the Judiciary.

    13 mars 2025 · IntroReferral

  16. Introduced in Senate

    13 mars 2025 · IntroReferral

  17. Introduced in Senate

    13 mars 2025 · IntroReferral

Sponsorship

3 cosponsors

Sponsor

Republican:Sen. Cornyn, John [R-TX]TX

Cosponsors

  • Democrat267%
  • Republican133%

Classification

Policy area

Commerce

Legislative subjects

Civil actions and liabilityCompetition and antitrustConsumer affairsDrug safety, medical device, and laboratory regulationHealth care costs and insuranceInflation and pricesIntellectual propertyJudicial review and appealsManufacturingPrescription drugs

Committees

1

  • Judiciary Committee

    Senate · Standing

    • Referred To13 Mar 2025
    • Markup By3 Apr 2025
    • Reported By10 Apr 2025
Pelosi Tracker
Follow on XRejoignez notre Discord
PolitiquesProjets de loiPortefeuillesTarifsÀ proposMentions légalesConditions d'utilisationPolitique de confidentialité
English
© 2026 - Tous droits réservés. Propulsé par Vantara Labs
Ce site web est une plateforme indépendante et tierce. Il n'est pas affilié à, approuvé par ou associé de quelque manière que ce soit à Nancy Pelosi, son bureau ou ses représentants. Toute utilisation de son nom est uniquement à des fins de discussion d'informations publiques disponibles.Les informations fournies sur ce site web sont uniquement à des fins informatives et éducatives et ne sont pas destinées à servir de conseils financiers ou d'investissement, ni ne doivent être interprétées comme tels. Les données présentées ici proviennent de déclarations et dossiers publics. Bien que nous nous efforcions d'assurer l'exactitude, l'actualité et l'exhaustivité, nous ne garantissons pas que toutes les informations sont exemptes d'erreurs ou à jour.Le support est disponible en anglais. Certaines traductions sont automatiques.